Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Ginger/valerian

This article was originally published in The Tan Sheet

Executive Summary

Ginger/valerian: USP concludes there is lack of evidence to support use of ginger for prevention of nausea and vomiting, according to an informational monograph published by the U.S. Pharmacopeia in its January 1998 USP DI update. The December update to the USP DI also contains a final informational monograph for valerian finding insufficient evidence to support valerian's use for short-term treatment of insomnia. Standards monographs for these herbs will appear in the March update to National Formulary. An informational monograph in the December edition of USP DI discourages the use of comfrey, citing the botanical's ability to cause serious liver damage. Due to the negative safety profile, no standards monograph will be published for the substance...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel